GenomeKey Genome Key Sepsis AMR Diagnosis Homepage

Powered by

Targeted Sepsis Treatment in Hours, not Days

Using next generation DNA sequencing and novel machine learning, GenomeKey diagnoses bacterial presence, species and antimicrobial resistance in only hours, not days, at low cost.

This saves lives, saves money, and saves our last antibiotics for when we really need them.

  • GenomeKey uses novel A.I. for bacterial AMR analysis

    Novel A.I.

  • GenomeKey's solutions integrate seamlessly into your existing ecosystems

    Integrated Solutions

  • GenomeKey have tried and tested results across a wide range of species-antibiotic combinations

    Proven Results

Sepsis kills more people than Cancer. It can affect anyone, of any age, and can kill in just hours.

Today it takes up to 3 days to determine which antibiotics will effectively treat a bacterial infection. This time window is absolutely critical for septic patients, as 1 in 3 deaths from Sepsis have already occurred by this time.

The Time Is Right For New Tools

End-to-end Microbiology Solutions

Once embedded in a hospital, our automated medical benchtop device will replace today's blood culture, providing rapid positive/negative identification of bacterial DNA in just 1.5 hours, species identification in 2 hours, and antimicrobial susceptibility analysis in as little as 4 hours.

Our systems are automated, light-weight and scalable, integrating into your existing ecosystem with ease.

Our A.I. is Explainable and Open

We believe Artificial Intelligence must be explainable and informative in the decisions it makes. Our platform provides a detailed breakdown of the basis of its AMR decision. By providing a complete description of which genes and mutations informed the decision of AMR, the system enables the microbiologist to better interpret the information provided. This also enables the advancement of our understanding of microbial resistance through the identification of new genomic regions.

Unlimited Potential

Unlike conventional AMR analysis which can only look at small chunks of DNA at a time, we use Whole Genome Sequencing, letting us analyse the entire genome at once. Seeing the whole picture allows us to identify much more complex genetic markers, enabling AMR predictions with next generation accuracy.

Our species agnostic system allows us to apply this technology to absolutely any bacteria-antibiotic pairing, empowering us to tackle Sepsis on all fronts.

What Sets Us Apart?

  • World leaders of AMR prediction

    We have achieved a world leading accuracy of 99.8% for predicting Staphylococcus aureus resistance, as well as far surpassing conventional techniques for Mycobacterium tuberculosis. Our accuracies and breadth of bacteria/drug support are only improving with time.

  • Integration into existing ecosystems

    Our technology requires very minimal hardware and training, and can be used by anyone through our client interface. We fit into your existing ecosystem with bare minimum interruption, with realtime updates to our ML models to give you the best results, all the time.

  • Scalable technology

    Our cloud scalable design allows for easy integration of further prediction algorithms, enabling us to quickly expand to analysis of other species, and test against additional antibiotics whilst scaling instantly to meet client demand.

  • Security

    We understand the value of data. That's why we've built security into the foundations of our service, using the most trusted security technologies to ensure your data is safe from the second it touches the internet, whilst ensuring maximum availability of our service.

  • Bringing treatment to those who need it

    Our low cost, low requirement technology allows us to provide our services where they are needed most. GenomeKey can integrate into remote and developing regions just as easily as world health leaders.

  • Furthering AMR research

    Our genomic relevance heatmaps allow for new insights into the causes of AMR. We also hope to expand beyond AMR, to further scientific understanding of human genetic disease.

Want to find out more?

Get in touch with us, and we'll be happy to discuss how we can best work together.